Wegovy firm unexpectedly forces boss to step down
Summary
Novo Nordisk, the company behind popular weight-loss drugs like Wegovy and Ozempic, is replacing its chief executive, Lars Fruergaard Jørgensen, due to challenges in the weight-loss market and a significant drop in its market value. Jørgensen has led the company since 2017 and will remain in his role until a new leader is appointed.Key Facts
- Novo Nordisk's market value has dropped by about half in the last year.
- Lars Fruergaard Jørgensen has been CEO since 2017.
- Competitors like Eli Lilly are gaining in the weight-loss drug market.
- The Novo Nordisk Foundation is involved in the decision to replace the CEO.
- Former CEO Lars Rebien Sørensen will have a larger role on the board.
- Many analysts were surprised by the sudden leadership change.
- Sales grew by over 25% to more than 290bn Danish kroner last year, but growth is now slowing.
- The company projects future sales growth of 13% to 21%.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
